

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

POLL RESULTS OF 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 3, 2025

The board of directors (the “**Board**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) is pleased to announce that the poll results of the 2025 first extraordinary general meeting (the “**EGM**”) of the Company was convened at 1:00 p.m. on Friday, January 3, 2025 at 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC. References are made to the notice of the EGM and the circular of the Company dated December 19, 2024 (the “**Circular**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF 2025 FIRST EXTRAORDINARY GENERAL MEETING

The EGM was convened by the Board and chaired by Dr. Wu Yusheng, the Chairman of the Board. All of the Directors, namely, Dr. Wu Yusheng, Dr. Jiang Mingyu, Dr. Li Jun, Dr. Gu Eric Hong, Dr. Meng Xiaoying, Mr. He Chao, Dr. Ding Zhao, Mr. Zhang Senquan, Dr. Leng Yuting, Dr. Xu Wenqing and Dr. Shen Xiuhua attended the EGM in person or by electronics means. The convening of and the procedures for holding the EGM and the voting procedures at the EGM were in compliance with the requirements of the PRC Company Law and the Articles of Association. The poll results of the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the proposed adjustment to remuneration of the executive Directors and the independent non-executive Directors:			
(i)	To consider and approve the proposed adjustment to remuneration of Dr. Wu Yusheng;	32,065,810 (81.66%)	7,200,000 (18.34%)	0 (0.00%)

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
(ii)	To consider and approve the proposed adjustment to remuneration of Dr. Jiang Mingyu;	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
(iii)	To consider and approve the proposed adjustment to remuneration of Mr. Zhang Shenquan;	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
(iv)	To consider and approve the proposed adjustment to remuneration of Dr. Leng Yuting;	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
(v)	To consider and approve the proposed adjustment to remuneration of Dr. Xu Wenqing;	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
(vi)	To consider and approve the proposed adjustment to remuneration of Dr. Shen Xiuhua.	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
2.	To consider and approve the proposed purchase of fixed assets.	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
3.	To consider and approve the proposed establishment of a wholly-owned subsidiary in Hong Kong.	170,515,810 (100.0%)	0 (0.00%)	0 (0.00%)
4.	To consider and approve the proposed authorization to the board of directors in respect of external investment and acquisition and disposal of assets.	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
5.	To consider and approve the proposed establishment of a wholly-owned subsidiary for macromolecular drug R&D.	163,315,810 (95.78%)	7,200,000 (4.22%)	0 (0.00%)
Special Resolution		Number of votes (%)		
		For	Against	Abstain
6.	To consider and approve the proposed amendments to the Articles of Association.	170,515,810 (100.0%)	0 (0.00%)	0 (0.00%)

Note: All percentages are rounded up to two decimal places.

Please refer to the Circular for details of each of the above resolutions.

As more than half of the votes were cast in favour of ordinary resolutions (1) to (5) and more than two thirds of the votes were cast in favour of special resolution (6), the above ordinary resolutions (1) to (5) and special resolution (6) were duly passed at the EGM by way of poll by the Shareholders. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As at the date of the EGM, the total number of issued Shares was 370,835,818 Shares, comprising 192,586,173 H Shares and 178,249,645 Unlisted Shares. To the best of the Director's knowledge, information and belief, and according to applicable PRC law, regulations and regulatory requirements and as disclosed in the Circular, Dr. Wu Yusheng, Changxing Caiyuan, Changxing Gangyuan, Changxing Liyuan and Tetranov Pharmaceutical (who collectively hold 45,937,500 H Shares and 85,312,500 Unlisted Shares) are required to abstain from voting on the resolution in relation to adjustment to remuneration of Dr. Wu Yusheng. Save as disclosed above, there were no Shares entitling Shareholders to attend the EGM and abstain from voting in favor of the resolutions pursuant to the Rule 13.40 of the Listing Rules and none of the Shareholders are required to abstain from voting at the EGM pursuant to the Listing Rules. No Shareholders have stated their intention in the Circular to vote against any resolutions or to abstain from voting at the EGM. As of the date of the EGM, there were (i) no H Shares repurchased and held by the Company in treasury ("**Treasury Shares**") (including any Treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of the Treasury Shares have been exercised at the EGM; and (ii) no repurchased Shares and therefore no Shares are pending cancellation and should be excluded from the total number of issued Shares entitled to attend and vote on all the resolutions at the EGM.

The Shareholders or their proxies present at the EGM held 170,515,810 Shares with voting rights in aggregate, representing approximately 45.98% of the total number of issued Shares as of the date of the EGM.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong
January 3, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.